Charles Chen – Vice Chairman & CEO, Medigen Vaccine Biologics Corp.…
Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s…
Address:
Tel: 886-2-2655-8133
In view of the need for an inter-agency task to carry out the promotion of the biotechnology and pharmaceutical high-tech industries, in November 1995 the Executive Yuan approved the key points for establishing the Biotechnology and Pharmaceutical Industries Program Office (BPIPO, MOEA). In February 1996 the BPIPO was formerly established to implement and promote the biotechnology industry’s development policy and act as a bridge for communication, coordination and integration among agencies. In December 2001, The Executive Yuan’s One-Stop-Service Office for the Biotechnology Industry was established under the BPIPO, with the office being responsible for the integration and coordination of local organizations involved in the various biotech-related approval and application processes, to build up a sound development environment for the biotech industry. The Director of the Industrial Development Bureau, MOEA acted as convener of the Program Office and formed a committee including the heads of the Executive Yuan’s Department of Health; Environmental Protection Administration; Council for Economic Planning and Development; National Science Council; Council of Agriculture; Science & Technology Advisory Group (STAG); Committee for the Development Fund; Department of Industrial Technology, MOEA; Intellectual Property Office, MOEA; and related government agencies; and representatives, academics, and experts from major research organizations and industry to form an inter-agency promotional organization.
The role of the Program Office is to serve as a window for the exchange of vital information between domestic and foreign industry, and to aggressively promote investment in Taiwan. In so doing, the Program Office hopes to accelerate the upgrading of Taiwan’s biotechnology and pharmaceutical industries and promote Taiwan to become an R&D, manufacturing and operations center for the Asia Pacific region, and furthermore to forge ahead to establish a global operations center.
Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s…
Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their…
Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody…
Taiwan Bio Industry Organization Chairman Dr Johnsee Lee outlines the Taiwanese biopharmaceutical industry’s…
Taiwan, although small in size, boasts a strong culture of innovation as well as a universal healthcare system that…
Long overshadowed by larger and more well-known neighbours, the island of Taiwan is nonetheless cultivating an…
While Taiwanese pharmaceutical and biotech players have traditionally set their sights on the US as a key market,…
All country managers of multinational pharma companies need to strike the balance between having a global outlook…
Nutrarex Biotech is a Taiwanese private label contract manufacturer of functional supplements, exclusively…
In an effort to enhance trade and cooperation with other countries in the region and reduce dependency on mainland…
Within Taiwan’s evolving medical device sector, many innovative startups are exploring breakthrough ideas which…
Mark Yang, CEO of GaleMed, elaborates on the medical device manufacturer’s transition from a privately-owned…